Get access

REPORT: Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America

Authors

  • John Mulhall MD,

    1. Weill Medical College of Cornell University—Department of Urology, New York, NY, USA;
    Search for more papers by this author
  • Patrick Teloken MS,

    Corresponding author
    1. Fundação Faculdade Federal de Ciências Médicas de Porto Alegre—Urology, Porto Alegre, Brazil;
      Patrick Teloken, MS, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, 245, Sarmento Leite St. Porto Alegre Rio Grande do Sul 90050-170, Brazil. Tel: 55 51 33887013; Fax: 55 51 33281975; E-mail: patrickteloken@gmail.com
    Search for more papers by this author
  • Gerald Brock MD,

    1. University of Western Ontario—Urology, London, ON, Canada;
    Search for more papers by this author
  • Edward Kim MD

    1. University of Tennessee at Knoxville—Urology, Knoxville, TN, USA
    Search for more papers by this author

Patrick Teloken, MS, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, 245, Sarmento Leite St. Porto Alegre Rio Grande do Sul 90050-170, Brazil. Tel: 55 51 33887013; Fax: 55 51 33281975; E-mail: patrickteloken@gmail.com

ABSTRACT

Because of increasingly sedentary lifestyles and diets higher in saturated fats, obesity and dyslipidemias are common and increasing in prevalence in Westernized countries. Longitudinal population-based studies clearly demonstrate that dyslipidemias and obesity, as well as factors such as hypertension, diabetes, and smoking, are major risk factors for atherosclerosis. Both clinical and animal models of endothelial dysfunction confirm that atherosclerosis leads to increased cerebrovascular and cardiovascular morbidity. Clinical studies with hypolipidemic agents demonstrate that hydroxy-3-methylglutaryl coenzyme A reductase inhibitors can decrease the risk of vascular morbidity. An increasing body of evidence from animal models demonstrates that hypercholesterolemia and atherosclerosis are risk factors for the development of erectile dysfunction (ED). This causal relationship between obesity and dyslipidemias with the development of ED in humans still needs further definition with convincing peer-reviewed scientific studies. The challenge for the future will be to define the benefit of controlling obesity and dyslipidemias on the development of ED and improvement of erectile function. Mulhall J, Teloken P, Brock G, and Kim E. Obesity, dyslipidemias and erectile dysfunction: A report of a subcommittee of the sexual medicine society of North America. J Sex Med 2006;3:778–786.

Get access to the full text of this article

Ancillary